Condition: Advanced Solid Tumor · Uveal Melanoma, Metastatic · Cutaneous Melanoma · Sponsor: MonTa Biosciences ApS
The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours. The trial is designed to provide data for further clinical development of MBS8(1V270)
This description comes directly from the study's public registry record.
Simon S Jensen, PhD · +45 5118 6306 · simonjensen@montabiosciences.com
Steven Glazer, MD · +45 25674434 · stevenglazer@montabiosciences.com
Always discuss trial participation with your own doctor first.
| Herlev and Gentofte Hospital, Center for Cancer Research | Herlev, Denmark | Recruiting |
| Institut Catalá de Oncologia - Hospital Duran i Reynals. | Barcelona, Spain | Not Yet Recruiting |
| Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD) | Madrid, Spain | Recruiting |
| Centro Integral Oncológico Clara Campal (CIOCC) | Madrid, Spain | Recruiting |
| Consorcio Hospital General Universitario de Valencia | Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04855435